| 產(chǎn)品名稱 | DCC 2036 - Rebastinib |
| 產(chǎn)品貨號(hào) | Axon 2123 CAS [1020172-07-9] MF C30H28FN7O3MW 553.59 Purity: 99% Soluble in DMSO Description An orally active Bcr-ABL inhibitor; being a ABL Switch-control inhibitor that potently inhibits BCR-ABL1 gatekeeper mutant T315I (IC50: 0.8 nM for native ABL1 and 4 nM in a ABL1T3151 kinase assay). DCC-2036 has efficacy in a mouse model of T315I-induced CML and against cells of patients with CML. In addition, DCC-2036 also inhibited the SRC family kinases SRC, LYN, FGR, and HCK, and the receptor TKs KDR, FLT3, and TIE2, but not c-KIT (IC50 of 34 nM, 29 nM, 38 nM, 40 nM, 4 nM, 2 nM, 6 nM, and 481 nM respectively) References Certificates Categories Extra info WW Chan et al. Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036. Cancer Cell 2011, 19(4), 556–568.? ? CA Eide et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res. 2011, 71(9), 3189-95.? Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology BCR-ABL EC 2.7.10.1 An orally active Bcr-ABL inhibitor Chemical name 4-(4-(3-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)-N-methylpicolinamide Parent CAS No. [1020172-07-9] Order Size Unit Price Stock 5 mg €125.00 In Stock |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
DCC 2036 - RebastinibAxon 2123 CAS [1020172-07-9] MF C30H28FN7O3
Description
An orally active Bcr-ABL inhibitor; being a ABL Switch-control inhibitor that potently inhibits BCR-ABL1 gatekeeper mutant T315I (IC50: 0.8 nM for native ABL1 and 4 nM in a ABL1T3151 kinase assay). DCC-2036 has efficacy in a mouse model of T315I-induced CML and against cells of patients with CML. In addition, DCC-2036 also inhibited the SRC family kinases SRC, LYN, FGR, and HCK, and the receptor TKs KDR, FLT3, and TIE2, but not c-KIT (IC50 of 34 nM, 29 nM, 38 nM, 40 nM, 4 nM, 2 nM, 6 nM, and 481 nM respectively)
An orally active Bcr-ABL inhibitor
Chemical name4-(4-(3-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)-N-methylpicolinamide Parent CAS No.[1020172-07-9] |
| 產(chǎn)品資料 |
